Tissue-Selective Estrogen Complex and Breast

Dong-Yun Lee
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Although estrogen-progestin therapy has traditionally been standard care for postmenopausal women with an intact uterus experiencing bothersome menopausal symptoms, concerns about side effects related to menopausal hormone therapy (MHT) have led to a dramatic decrease in MHT use over recent decades. As many MHT side effects are now believed to be associated with the progestin component of MHT, efforts have been made to develop a progestin-free alternative to conventional MHT. Recently, a tissue-selective estrogen complex (TSEC), a combination of conjugated estrogen and bazedoxifene, was developed as a progestin-free MHT and is now approved and used worldwide for the relief of vasomotor symptoms and the prevention of bone loss in postmenopausal women. Replacement of synthetic progestin with bazedoxifene could allow more favorable safety profiles, such as those for pain or tenderness, mammographic density, and cancer incidence, for the breast. This review examined the effects of the TSEC on breasts and demonstrated evidence from preclinical and clinical studies supporting TSEC use in clinical practice.

Key Words: Bazedoxifene, Breast, Conjugated estrogen, Tissue-selective estrogen complex

INTRODUCTION

For a long period, menopausal hormone therapy (MHT) has been the gold standard for relieving vasomotor symptoms in postmenopausal women [1]. Although the main component of MHT is estrogen, progestogen should be added to protect the endometrium in women with an intact uterus.

However, the use of progestogen has been associated with side effects, and breast discomfort is one of the most common problems. Breast discomfort can increase anxiety and lead to unnecessary interventions, which can lower satisfaction and compliance with MHT. In addition, concern about the increased risk of breast cancer related to progestin has been strongly emphasized since the Women’s Health Initiative [2,3]. Experience of and concern about the side effects involving the breast are important reasons for discontinuance of MHT; therefore, these issues should be prioritized. Moreover, a regimen with fewer effects on the breast is favorable for the provision of safe and convenient MHT.

Recently, a selective estrogen receptor modulator (SERM) was combined with conjugated estrogen (CE), and a new progestin-free tissue-selective estrogen complex (TSEC) was developed. Currently, a TSEC consisting of 0.45 mg CE and 20 mg bazedoxifene (BZA) is used in the management of vasomotor symptoms and prevention of osteoporosis.

The objective of this review was to evaluate the effects of the TSEC on breasts and demonstrated evidence from preclinical and clinical studies supporting TSEC use in clinical practice.
morphological effects, BZA demonstrated less agonistic activity and a stronger antagonistic effect on CE, relative to raloxifene or lasofoxifene, in the mammary gland.

In addition, when comparing the effects of estradiol, CE, and BZA on mammary gland and breast cancer xenografts, BZA effectively blocked CE-stimulated estrogenic effects on ductal length, terminal end bud development, cell proliferation, apoptosis, and estrogen-responsive gene expression. In human xenografts, BZA inhibited tumor progression via estrogen [5]. Moreover, CE was much less potent than estradiol in terms of proliferation, apoptosis, and gene expression. These findings suggest that CE and BZA could block estrogen action in both benign and malignant breast tissue.

Further, in a preclinical trial, 95 ovariectomized cynomolgus macaques were randomly assigned to receive no treatment, BZA, CE, or BZA and CE with women’s daily equivalent doses, and breast effects were compared after 6 months of treatment. The results showed that total epithelial density, lobular enlargement, and Ki67 immunolabeling in the terminal ducts were lower with CE and BZA, relative to CE alone. This combination also antagonized ER-alpha regulated genes significantly and reduced ER-alpha protein expression and markers of ER-alpha activity [6]. Clinically, these findings could support a lower breast-cancer risk profile for CE and BZA relative to those for other estrogen-progestin therapies.

To explore the mechanism of CE and BZA, the impact of gene expression and the recruitment of cofactor peptides to ER-alpha were compared across various estrogens with or without SERMs. CE was more potent than estradiol in mediating ER-alpha interaction with cofactor peptides, and a combination of CE and BZA showed maintenance of CE-dependent cofactor recruitment on estrogen-receptor alpha at lower efficacy, which differed from receptor confirmation shown with other SERMs [7]. This finding indicated that combinations of other estrogens and SERM preparations might not demonstrate the beneficial effects shown by CE and BZA.

Moreover, several studies have evaluated the effects of CE and BZA on human breast tissue, particularly in human breast cancer cell line MCF-7. In a GeneChip microarray to compare gene expression profiles of SERMs alone or combined with CE, different SERMs showed different gene expression patterns demonstrating differences in the ability to antagonize CE-induced cell proliferation. Antagonistic activity was significantly higher with the combination of CE and BZA, relative to other SERMs [8].

When comparing estradiol and CE alone on proliferation and apoptosis, CE stimulated MCF-7 growth at a higher concentration relative to estradiol, and the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker relative to those of estradiol. BZA effectively blocked the stimulatory actions of CE and reserved antiapoptotic action [9].

In addition, CE was less effective than estradiol in the recruitment of extracellular signal-regulated kinase2 and the stimulation of proliferation of breast cancer cells. Moreover, BZA antagonized CE stimulation of gene expression and cell proliferation in the TSEC [10].

The results of these preclinical studies indicated that agonistic and antagonistic activity was ideally balanced, and lack of breast stimulation was observed with a combination of CE and BZA. In addition, these findings demonstrated the antiestrogenic effects of the TSEC on breast tissue in postmenopausal women.

Clinical studies

The effects of the TSEC on the breast in clinical studies can be divided as follows: symptoms (breast pain or tenderness), markers (mammographic density), and clinical outcomes (breast lesion or cancer). Table 1 presents the results for the breast in five SMART (Selective estrogens, Menopause, And Response to Therapy) trials.

**Breast pain or tenderness**

Breast discomfort, such as pain or tenderness, is a common side effect of MHT and could be associated with the risk of breast cancer when it occurs after estrogen-progestin therapy [11].

In the main SMART-5 study, breast tenderness was reported in 3.4% of TSEC users; this rate was similar to that observed for a placebo (3.0%) and lower relative to that for CE 0.45 mg/medroxyprogesterone acetate 1.5 mg (10.9%). Moreover, none of the TSEC users discontinued the medication because of breast tenderness [12]. In the other SMART studies, SMART-1 to -4, breast pain or tenderness did not increase in TSEC users when compared to a placebo [13-16].

Further, in a recent retrospective cohort study, 82 postmenopausal women who switched to TSEC from other hormone therapies because of vaginal bleeding or breast discomfort were assessed. Of these women,
47.3% cited breast discomfort as the reason for the switch. Almost all women with breast discomfort or vaginal bleeding had experienced an improvement in symptoms following the switch from conventional MHT to the TSEC [17].

**Breast density**

Breast density is a well-known, independent risk factor for breast cancer [18]. In the Women’s Health Initiative, estrogen alone was compared to estrogen-progestin therapy, which increased breast density by 4.9% after 2 years of use [19]. Although the association between increased breast density during MHT and breast cancer risk remains unclear, increased breast density during MHT could reduce the sensitivity and specificity of mammography and interfere with breast cancer screening. Therefore, MHT regimens with fewer effects on breast density would be favorable.

In an ancillary study of SMART-1, mammographic density reduced significantly after 24 months of TSEC use (~0.39%) in 129 women; this rate was similar to that for a placebo (~0.42%) and consistent with the expected decrease over time [20]. In addition, in a sub-study of SMART-5, no significant difference in breast density changes was observed between TSEC and placebo users after 12 months of treatment [21]. Moreover, in pooled data from five SMART trials, which included 1,585 TSEC users and 1,241 placebo users, CE and BZA did not increase breast density for up to 2 years, unlike CE and medroxyprogesterone acetate [22].

**Breast lesions**

In the SMART-4 study, the occurrence of adverse events involving the breast, such as breast cysts (0.3%, n = 1) and fibrocystic breast disease (0.6%, n = 2), did not differ between the TSEC and a placebo [16]. In the main SMART-5 study, abnormal mammograms were observed in four women using TSEC (0.9%); this rate did not differ significantly from that with a placebo (0.2%, n = 1). In addition, the breast cancer rate for TSEC users was 0.4% (n = 2), which was similar to that for the placebo (0.2%, n = 1) [12]. Further, in pooled data from SMART-1, SMART-4, and SMART-5, the incidence rates for abnormal mammograms at 12 months with TSEC (2.6%) and placebo (3.2%) use were similar [22].

Moreover, a recent study assessed 1-year changes in the imaging of breast lesions following the switch from other hormone therapies to TSEC in women who had previously shown breast lesions. The results demonstrated that most breast lesions identified via ultrasonography or mammography (88.4%) remained unchanged after 1 year of TSEC use [17]. This finding, which is consistent with those of previous studies showing no difference in newly detected breast lesions during TSEC use, when compared with a placebo, emphasizes the safety profile of TSEC use for the breast.

However, breast cancer risk in TSEC users has not been established because of the small number of events and insufficient duration of clinical trials (up to 2 years). Nevertheless, in a pooled analysis of all 5 SMART trials, the relative risk of breast cancer for the TSEC was 1.1 (95% confidence interval, 0.3–3.8), which was similar to that for a placebo [22].

**CONCLUSION**

The TSEC containing CE and BZA is a new, progestin-free MHT. According to preclinical and clinical data, the TSEC does not stimulate the breast or increase breast density, the incidence of breast pain or tenderness, or the risk of breast cancer (Fig. 1). Con-
Considering the efficacy and safety profile of the TSEC for the breast, it is promising in an era in which long-term MHT is favored for postmenopausal women.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017; 24: 728-53.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
3. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
4. Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009; 150: 1897-903.
5. Song Y, Santen RJ, Wang JP, Yue W. Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice. Endocrinology 2012; 153: 5706-15.
6. Ethun KE, Wood CE, Register TC, Cline JM, Appt SE, Clarkson TB. Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys. Menopause 2012; 19: 1242-52.
7. Berrodin TJ, Chang KC, Komm BS, Freedman LP, Nagpal S. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol 2009; 23: 74-85.
8. Chang KC, Wang Y, Bodine PV, Nagpal S, Komm BS. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010; 118: 117-24.
9. Song Y, Santen RJ, Wang JP, Yue W. Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro. Endocrinology 2013; 154: 656-65.
10. Madak-Erdogan Z, Gong P, Katzenellenbogen BS. Differential utilization of nuclear and extranuclear receptor signaling pathways in the actions of estrogens, SERMs, and a tissue-selective estrogen complex (TSEC). J Steroid Biochem Mol Biol 2016; 158: 198-206.
11. Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson G, et al. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials. Breast Cancer Res Treat 2012; 132: 275-85.
12. Pinkerton JV, Harvey JA, Lindsay R, Pan K, Chines AA, Mirkin S, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014; 99: E189-98.
13. Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009; 92: 1025-38.
14. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009; 16: 1116-24.
15. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010; 17: 281-9.
16. Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/ conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013; 16: 338-46.
17. Kim SE, Lee DY, Choi D. Tissue-selective estrogen complex for...
women who experience breast discomfort or vaginal bleeding when on hormone therapy. Menopause 2019; 26: 383-6.
18. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005; 6: 798–808.
19. McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005; 97: 1366–76.
20. Harvey JA, Pinkerton JV, Baracat EC, Shi H, Chines AA, Mirkin S. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause 2013; 20: 138-45.
21. Pinkerton JV, Harvey JA, Pan K, Thompson JR, Ryan KA, Chines AA, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol 2013; 121: 959–68.
22. Mirkin S, Pinkerton JV, Kagan R, Thompson JR, Pan K, Pickar JH, et al. Gynecologic safety of conjugated estrogens plus bazedoxifene: pooled analysis of five phase 3 trials. J Womens Health (Larchmt) 2016; 25: 431–42.